Journal
ONCOIMMUNOLOGY
Volume 1, Issue 3, Pages 404-406Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.19310
Keywords
tolerance; p53; NY-ESO-1; tumor antigen; cancer vaccine; CD8 T lymphocytes; Serum antibody
Categories
Ask authors/readers for more resources
Tumor antigens NY-ESO-1 and p53 both frequently induce spontaneous serum antibody in cancer patients. While NY-ESO-1-specific CD8(+) and CD4(+) circulating T-cells occur mainly in NY-ESO-1-seropositive patients, p53-specific circulating CD8(+) and CD4(+) T-cells are respectively undetectable and common in most individuals. Understanding T-cell split tolerance can help define suitable targets for immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available